NEW YORK (GenomeWeb) – Diagnostics firm Protagen announced a long-term collaboration agreement with Qiagen to provide pharmaceutical partners access to technology that would advance the development of protein-based companion tests for autoimmune disorders.

The terms of the agreement give Qiagen access to Protagen's proprietary SeroTag, an automated multiplex technology that can facilitate the discovery and validation of protein-based biomarker panels. SeroTag can measure autoantibody levels for thousands of antigens from a patient's single serum sample.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.